---
title: "VK2735 in Chronic weight management: Care management intervention strategies"
description: "Formulary evidence on VK2735 in Chronic weight management: Care management intervention strategies. Topics: Coverage criteria recommended by ICER for incretin anti-obesity medications; Step therapy and preferred formulary options; Medicare GLP-1 Bridge demonstration; BALANCE Model: negotiated prices, lifestyle support, and product eligibility; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Coverage criteria recommended by ICER for incretin anti-obesity medications

> “Payers could follow the example of the proposed criteria for Medicare coverage: 1) BMI ≥ 27 with prediabetes or established CV disease, 2) BMI ≥ 30 with uncontrolled hypertension, kidney disease, or heart failure, 3) BMI ≥ 35.”
> “Payers should consider having prior authorization approval apply to all doses, rather than require prior authorization for each dose separately, to minimize burden on prescribers and patients.”
> “Initial coverage will likely be for a period of 12 months, which is long enough for dose titration, assessment of side effects, and assessment of efficacy.”
> “Renewal of therapy: Payers should use a patient’s starting weight, not current weight, as the basis for judging whether further treatment is necessary.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.4-2"></a>

### Step therapy and preferred formulary options

> “Because of the budget impact of injectable semaglutide and tirzepatide, payers may still wish to employ step therapy, requiring enrollment in structured obesity management programs and/or trying less expensive medications.”
> “There is no justification for payers to make patients re-try weight loss programs or medications that they have previously tried and that have failed them.”
> “Payers may opt to have one drug from the newer GLP-1 RA class as the preferred formulary option.”
> “if there is a preferred formulary option, payers should have a rapid exceptions process for patients to switch to or continue the non-preferred option.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.4-3"></a>

### Medicare GLP-1 Bridge demonstration

> “The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”
> “In 2026, CMS will use a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies for the Medicare GLP-1 Bridge.”
> “Eligible beneficiaries will have a $50 copay.”
> “This means that the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary’s TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries.”

Source: [CMS Medicare GLP-1 Bridge (2026)](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)

<a id="topic-2.2.2.4-4"></a>

### BALANCE Model: negotiated prices, lifestyle support, and product eligibility

> “Under BALANCE, CMS negotiates lower prices directly with eligible GLP-1 manufacturers on behalf of State Medicaid agencies and Part D plans. Negotiations also address eligibility criteria for patients.”
> “All beneficiaries receiving GLP-1s for weight management under the BALANCE model in Medicaid will be provided with access to a lifestyle support program, provided by the manufacturer at no cost.”
> “Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements.”
> “Eligible manufacturers are those that are eligible for the initial negotiations or expect to market an eligible product by January 1, 2027.”
> “have clinical evidence that, at an FDA-approved dose, the product reduces body weight by at least 9.5% on average, according to the primary or secondary endpoint in a randomized clinical trial”
> “All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™.”

Source: [CMS BALANCE Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/balance)

<a id="topic-2.2.2.4-5"></a>

### Structured behavioral programs alongside pharmacotherapy

> “Interventions that combined pharmacotherapy with behavioral interventions reported greater weight loss and weight loss maintenance”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
